ATO inhibits tumor growth and angiogenesis of HCC by blocking the paracrine signaling of Ang-1 and Ang-2 through the inhibition of the p-Akt/HIF-1α pathway after IRFA. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.